此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估同种异体脐带间充质干细胞在 COVID-19 患者中的安全性和有效性 (UMSC01)

2026年9月21日 更新者:Ever Supreme Bio Technology Co., Ltd.

评估同种异体脐带间充质干细胞在重症和危重 COVID-19 患者中的安全性和有效性的无缝 I/IIa 期临床研究

This study is to explore the safety and efficacy of using UCMSC01 in patients with COVID-19 infection via IV stem cell administration. The novelty of the current UMSC01 treatment is the single IV infusion of UMSC01 to the worldwide emergency outbreaks of COVID-19. We hypothesize that sufficient UMSC01 retention in lung may modulate the systemic inflammatory responses.

研究概览

详细说明

The lead Phase I safety phase will further confirm the safety profile of UMSC01 in 5 COVID-19 patients each at two dose regimens and placebo.

To start the Phase IIa study, data analysis will be performed as soon as the 21-day treatment period has been completed in the three groups. With considerations of the pandemic status and clinical practice, only one of the two active treatment groups will be selected to complete the Phase IIa study, which will recruit 60 patients.

研究类型

介入性

注册 (估计的)

75

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Non-US
      • Taichung、Non-US、台湾、404
        • China Medical University Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Male or female aged 20 to 80 years old.

  2. Hospitalized severe and critical COVID-19 patients with laboratory confirmation by reverse-transcription polymerase chain reaction (RT-PCR) from nasopharyngeal/ oropharyngeal samples collected using standardized method.

  3. Pneumonia or interstitial lung damage that is confirmed by chest radiographs or computed tomography.

  4. Severe COVID-19 infection which meets any one of the following: 1) dyspnea (PR ≥ 30 times/min), 2) finger oxygen saturation ≤ 93% in the room air and resting state, 3) arterial oxygen partial pressure (PaO2)/oxygen absorption concentration (FiO2) ≤ 300 mmHg, 4) pulmonary imaging which shows that the focus progress > 50% within 24-48 hours, or

  5. Critically severe COVID-19 infection which meets any of the following: 1) respiratory failure treated by mechanical ventilation, 2) shock, 3) combined with other organ failure, 4) patients expected to need ICU monitoring and treatment.

  6. High sensitivity C-reactive protein (hs-CRP) serum level > 4.0 mg/dL.

  7. All female patients with child-bearing potential (between puberty and 2 years after menopause) should use appropriate contraception method(s) shown below, for at least 4 weeks after UMSC01 treatment and agree to maintain such contraceptive method(s) for another 4 weeks after UMSC01 treatment.

    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    2. Female sterilization (bilateral oophorectomy with or without hysterectomy) or tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, the reproductive status of the woman should be confirmed by the hormone level assessment.
    3. Male sterilization (at least 6 months prior to screening). For female subjects in the study, the vasectomized male partner should be the sole partner for that subject.
    4. Combination of any two of the following listed methods: (d.1 + d.2 or d.1 + d.3, or d.2 + d.3):

    d.1 Use of oral, injected, or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), such as hormone vaginal ring or transdermal hormone contraception.

    d.2 Placement of an intrauterine device (IUD) or intrauterine system (IUS). d.3 Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.

Exclusion Criteria:

  1. Pregnancy, lactation, and those who are not pregnant but did not, or unwilling to, take effective contraceptives measures 4 weeks before and after the treatment.
  2. Patients with malignant tumors or other serious systemic diseases.
  3. Patients with hemoglobin < 10 g, alanine aminotransferase (ALT) ≥ 5 × ULN, aspartate aminotransferase (AST) ≥ 5 × ULN, alkaline phosphatase (ALP) ≥ 5 × ULN, total bilirubin (TBILI) ≥ 2 × ULN, serum creatinine > 2.5 mg/dl, platelet counts < 100,000/μL, WBC < 3,000 cells/μL, or neutrophil counts < 1,000/μL at screening.
  4. Presence of barotrauma or hemodynamic instability defined as hypotension with diastolic blood pressure < 90 mmHg or mean arterial pressure (MAP) < 70 mmHg despite fluid expansion, and vasoactive support or pneumothorax at screening.
  5. Uncontrolled hypertension with systolic blood pressure > 170 mmHg and diastolic blood pressure > 100 mmHg which, in the investigator's judgment, would not make participation appropriate.
  6. Recent history of (within 2 years) ischemic heart disease or cerebrovascular attack, such as myocardial infarction, unstable angina, or stroke.
  7. Recent history (within 2 years) of hypercoagulable disorder, antiphospholipid syndrome, pulmonary embolism, or deep venous thrombosis.
  8. Condition other than COVID-19 that is projected to limit lifespan to ≤ 1 year.
  9. History of drug or alcohol abuse within the past 24 months.
  10. Unwilling to commit to follow-up visits.
  11. Patients who are participating in other clinical trials with an investigational product.
  12. Co-infection of HIV, tuberculosis, influenza virus, adenovirus, and other respiratory infection virus.
  13. Patients with other conditions that are not suitable to participate in this clinical study as determined by the investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:UMSC01

UMSC01 cells mixed with normal saline will be administered to patients after COVID-19 infection.

UMSC01 cells will be IV infusion with 12 months of follow up after treatment.

安慰剂比较:Placebo

Normal saline will be administered to patients after COVID-19 infection.

Normal saline will be IV infusion with 12 months of follow up after treatment.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Two Co-Primary Efficacy Endpoints
大体时间:21 days of the treatment period

Proportion of patients alive with sustained improvement within the 21 days of the treatment period (Proportion Analysis), which indicates the capability of UMSC01 to save more lives

21 days of the treatment period
Two Co-Primary Efficacy Endpoints
大体时间:21 days of the treatment period

Time (days) to reach sustained improvement within the 21 days of the treatment period (Time-to-Event Analysis), which indicates the capability of UMSC01 to enable patients to less suffer from the disease condition.

21 days of the treatment period

次要结果测量

结果测量
措施说明
大体时间
Secondary Efficacy Endpoints
大体时间:21 days of the treatment period

Proportion of enrolled patients alive on Day 21

21 days of the treatment period
Secondary Efficacy Endpoints
大体时间:21 days of the treatment period

Proportion of enrolled patients alive and free of respiratory failure on Day 21

21 days of the treatment period
Secondary Efficacy Endpoints
大体时间:21 days of the treatment period

Improvement of COVID 19 pneumonia confirmed by chest radiographs or computed tomography on Day 21 or on the day of discharge compared with baseline

21 days of the treatment period
Secondary Efficacy Endpoints
大体时间:21 days of the treatment period

Improvement of clinical symptoms including duration of fever in degrees C and respiratory failure on Day 21 or on the day of discharge compared with baseline

21 days of the treatment period
Secondary Efficacy Endpoints
大体时间:21 days of the treatment period

Duration of ventilator usage or oxygen therapy on Day 21 or on the day of discharge compared with baseline

21 days of the treatment period
Secondary Efficacy Endpoints
大体时间:21 days of the treatment period

Levels of tumor necrosis factor-alpha (TNF-α) in pg/ml, interleukin-6 (IL-6) in pg/ml and interleukin-10 (IL-10) in pg/ml, and C-reactive protein (hsCRP) in mg/dl on Day 21 or on the day of discharge compared to baseline

21 days of the treatment period
Secondary Efficacy Endpoints
大体时间:21 days of the treatment period

Troponin I level as assessed via serum blood samples on Day 21 or on the day of discharge compared with baseline

21 days of the treatment period
Secondary Efficacy Endpoints
大体时间:21 days of the treatment period

ICU admission rate on Day 21 or on the day of discharge with historical data

21 days of the treatment period
Secondary Efficacy Endpoints
大体时间:14 days of the treatment period

Percentage of subjects recorded in each severity rating based on Clinical classification of the COVID-19 (NCOSS scores from 1 to 8;higher scores mean a worse outcome) on Day 14 compared with historical data

14 days of the treatment period
Secondary Efficacy Endpoints
大体时间:21 days of the treatment period

Percentage of subjects recorded in each severity rating based on Clinical classification of the COVID-19 (NCOSS scores from 1 to 8;higher scores mean a worse outcome) on Day 21 compared with historical data

21 days of the treatment period
Secondary Efficacy Endpoints
大体时间:through study completion, an average of 1 year

Average time (days) for which the patients are alive and free of respiratory failure during the treatment period

through study completion, an average of 1 year
Secondary Efficacy Endpoints
大体时间:21 days of the treatment period

Proportion of patients who need ICU care on Day 21 based on the clinical indicative of admission to ICU

21 days of the treatment period
Secondary Efficacy Endpoints
大体时间:21 days of the treatment period

Proportion of patients who has been discharged form hospital on Day 21

21 days of the treatment period
Secondary Safety Endpoints
大体时间:21 days of the treatment period

Number of Participants with infusion-related and allergic reactions during the treatment period

21 days of the treatment period
Secondary Safety Endpoints
大体时间:through study completion, an average of 1 year

Secondary infection, treatment emergent adverse event (TEAE), serious adverse event (SAE), and suspected and unexpected serious adverse reaction (SUSAR) incidences over the study period. The toxicities will be assessed by CTCAE V5.0 during the whole study period (380 days)

through study completion, an average of 1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Woei C Shyu、Ever Supreme Bio Technology Co., Ltd.
  • 首席研究员:Long Bin Jeng、China Medical University Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年8月5日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2022年8月10日

首先提交符合 QC 标准的

2022年8月11日

首次发布 (实际的)

2022年8月15日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月21日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅